Global pharmaceutical firm AstraZeneca has invested an additional $100 million into its venture capital arm MedImmune Ventures. The additional investment has increased the total capital under management to $400 million.
MedImmune Ventures, in the past mostly focused on opportunities in the U.S., has started looking more broadly and has made its first investment in Australia. It makes equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.
Click here for the story from The Wall Street Journal.